News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Alexis Vandier has joined SERVIER as Global Asset leader for Vorasidenib
Photo: Alexis Vandier/LinkedIn
May 15, 2023, 11:51

Alexis Vandier has joined SERVIER as Global Asset leader for Vorasidenib

Thanks Katéri Cuvillier. I am very proud of joining Servier with an immediate focus on bringing new solution for patients with brain cancer. I have been lucky to meet great people at Servier and I feel privileged to join a global company with french roots which has been able to build such a great oncology franchise in very short time – Alexis Vandier

Source: Alexis Vandier/LinkedIn

Alexis Vandier Servier Vorasidenib
Special Coverage
Insight
Sep 7, 2025, 06:07
Amol Akhade: Key Insights from WCLC25
Voices
Sep 7, 2025, 06:06
Vedant Shah: Honored to Present Our Work at SOHO2025
Voices
Sep 7, 2025, 05:55
Chalothorn Wannaphut: Presenting at SOHO2025
Voices
Sep 7, 2025, 05:46
John McGrane: Everything You Need to Know About Biliary Tract Cancers
Voices
Sep 7, 2025, 05:24
Christian Rolfo: Amazing IASLC Academy 2025!
Voices
Sep 7, 2025, 05:18
Shreyas Kalantri: Two of My Posters Are Being Presented at WCLC25
Voices
Sep 7, 2025, 05:14
30 Days Until the Jimmy Fund Walk 2025 - Florez Lab
Voices
Sep 7, 2025, 05:09
Roberto Borea: Umberto Malapelle Opens the Plenary at WCLC25
Voices
Sep 7, 2025, 05:05
Rita Ahmad: Sharing Exciting Updates on Immunotherapy in IBCL
Voices
Sep 7, 2025, 04:54
Herbert Loong: The ASCO International Affairs Committee 2025-26
Voices
Sep 7, 2025, 04:53
Luis E. Raez: Very Successful IASLC Latin America Session at WCLC25
Science
Sep 7, 2025, 04:45
Iannis Aifantis: The pre-T Cell Receptor as an Immunotherapy Target in T Cell Leukemia